Sugi Predict

Sugi Predict / Compounds / SCHEMBL7948445

SCHEMBL7948445

SCHEMBL7948445

COC(=O)c1cc(I)c(O)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 3/20 0.46
▸ ABL1 P00519 1/20 0.45
▸ CA12 O43570 2/20 0.44
▸ CA1 P00915 2/20 0.44
▸ CA2 P00918 2/20 0.44
▸ CA7 P43166 2/20 0.44
▸ CA9 Q16790 2/20 0.44
▸ CA14 Q9ULX7 2/20 0.44
▸ PDK2 Q15119 1/20 0.44
▸ PDK4 Q16654 1/20 0.44
▸ LMNA P02545 5/20 0.43
▸ TSHR P16473 2/20 0.43
▸ CFTR P13569 1/20 0.43
▸ GAA P10253 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31187062 0.93 CA12 (0.44) NR4A2ABL1CA12CA1CA2
SCHEMBL17892934 0.93 CA12 (0.44) NR4A2ABL1CA12CA1CA2
SCHEMBL2849661 0.85 CFTR (0.45) NR4A2ABL1CA12CA1CA2
SCHEMBL25340450 0.85 CA12 (0.50) NR4A2CA12CA1CA2CA7
SCHEMBL31024714 0.85 CA12 (0.50) NR4A2CA12CA1CA2CA7
SCHEMBL14885169 0.85 CA12 (0.50) NR4A2ABL1CA12CA1CA2
SCHEMBL2650105 0.83 GAA (0.50) NR4A2ABL1CA12CA1CA2
SCHEMBL17239556 0.82 CFTR (0.43) NR4A2ABL1CA12CA1CA2
SCHEMBL7082612 0.81 GAA (0.46) NR4A2ABL1LMNATSHRCFTR
SCHEMBL8331820 0.81 GAA (0.53) ABL1LMNATSHRCFTRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049326-A1 TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 BIOCRYST PHARMACEUTICALS, INC. (US) 2025-03-06 — — WO disclosed
CN-113302184-B 1,3, 4-Oxadiazolinone compounds and medicaments 日本新药株式会社 2024-11-22 — — CN disclosed
WO-2022148442-A1 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 武汉人福创新药物研发中心有限公司 2022-07-14 — — WO disclosed
WO-2022148442-A1 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 武汉人福创新药物研发中心有限公司 2022-07-14 — — WO disclosed
CN-114716478-A 6-substituted phosphoryl quinazoline derivative and preparation method and application thereof 武汉人福创新药物研发中心有限公司 2022-07-08 — — CN disclosed
US-20190040087-A1 MICROBIOCIDALLY ACTIVE BENZOXABOROLES SYNGENTA PARTICIPATIONS AG (CH) 2019-02-07 — — US disclosed
US-20190040087-A1 MICROBIOCIDALLY ACTIVE BENZOXABOROLES SYNGENTA PARTICIPATIONS AG (CH) 2019-02-07 — — US disclosed
US-10040806-B2 Microbiocidally active benzoxaboroles SYNGENTA PARTICIPATIONS AG (CH) 2018-08-07 — — US disclosed
US-10040806-B2 Microbiocidally active benzoxaboroles SYNGENTA PARTICIPATIONS AG (CH) 2018-08-07 — — US disclosed
US-10040806-B2 Microbiocidally active benzoxaboroles SYNGENTA PARTICIPATIONS AG (CH) 2018-08-07 — — US disclosed
EP-3107921-A1 MICROBIOCIDALLY ACTIVE BENZOXABOROLES Syngenta Participations AG (CH) 2016-12-28 — — EP disclosed
US-20160347773-A1 MICROBIOCIDALLY ACTIVE BENZOXABOROLES SYNGENTA PARTICIPATIONS AG (CH) 2016-12-01 — — US disclosed
US-20160347773-A1 MICROBIOCIDALLY ACTIVE BENZOXABOROLES SYNGENTA PARTICIPATIONS AG (CH) 2016-12-01 — — US disclosed
US-20160347773-A1 MICROBIOCIDALLY ACTIVE BENZOXABOROLES SYNGENTA PARTICIPATIONS AG (CH) 2016-12-01 — — US disclosed
WO-2015121442-A1 MICROBIOCIDALLY ACTIVE BENZOXABOROLES SYNGENTA PARTICIPATIONS AG (CH) 2015-08-20 — — WO disclosed
WO-2015121442-A1 MICROBIOCIDALLY ACTIVE BENZOXABOROLES SYNGENTA PARTICIPATIONS AG (CH) 2015-08-20 — — WO disclosed
CN-1097579-C Ortho-substituted benzoylguanidines, process for their preparation, their use as medicament, and medicament comprising them HOECHST AG (DE) 2003-01-01 — — CN disclosed
US-6262123-B1 AS ANTIARRHYTHMIC AGENTS HAVING CARDIOPROTECTIVE COMPONENT, FOR PROPHYLAXIS AND TREATMENT OF INFARCTION AND ANGINA PECTORIS; FOR INHIBITION OF PATHOPHYSIOLOGICAL PROCESSES ASSOCIATED WITH GENESIS OF ISCHEMICALLY INDUCED DAMAGE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-07-17 — — US disclosed
US-6075054-A Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them HOECHST AKTIENGESELLSCHAFT (DE) 2000-06-13 — — US disclosed
CN-1194976-A Ortho-substituted benzoylguanidines, process for their preparation, their use as medicament, and medicament comprising them HOECHST AG (DE) 1998-10-07 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190040087-A1 MICROBIOCIDALLY ACTIVE BENZOXABOROLES MPO, BROX, MANBA NR4A2 1870/4885ABL1 3005/4885CA12 3032/4885
US-20160347773-A1 MICROBIOCIDALLY ACTIVE BENZOXABOROLES MPO, BROX, MANBA NR4A2 1870/4885ABL1 3005/4885CA12 3032/4885
US-10040806-B2 Microbiocidally active benzoxaboroles MPO, BROX, MANBA NR4A2 1870/4885ABL1 3005/4885CA12 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.